Ignite Creation Date:
2024-05-06 @ 9:49 AM
Last Modification Date:
2024-10-26 @ 12:20 PM
Study NCT ID:
NCT03082729
Status:
COMPLETED
Last Update Posted:
2022-11-10
First Post:
2017-02-22
Brief Title:
Vascular Inflammation in Psoriasis - Apremilast
Sponsor:
University of Pennsylvania
Organization:
University of Pennsylvania
Study Overview
Official Title:
A Phase IV Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VIP-A
Brief Summary:
The purpose of the VIP-A study is to determine the effect of apremilast on aortic vascular inflammation cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis
Detailed Description:
The primary objectives of this study are to determine the effect of apremilast on aortic vascular inflammation cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis Fluorodeoxyglucose FDG - positron emission tomography PETcomputed tomography CT will be used to assess vascular inflammation with multi-volumetric product tissue-to-background ratio and total atherosclerotic burden and body composition via volumetric quantification This is a year-long single arm open label study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 97509210 | OTHER_GRANT | Celgene | None |